Build a Research Clinic for Somatoform Patients

Sponsor
National Taiwan University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04835103
Collaborator
National Taiwan University Hospital, Yun-Lin Branch (Other)
1,000
1
2
12
83.6

Study Details

Study Description

Brief Summary

To investigate the effects of the two following interventions on somatoform patients:1. case management model2. psychotherapy, based on cognitive-behavioral therapy and biofeedback therapy

Condition or Disease Intervention/Treatment Phase
  • Behavioral: CM
  • Behavioral: P/T
N/A

Detailed Description

Patients with presentations of somatic symptoms and associated psychological features are named as "somatoform disorders" in psychiatric field. Because the patients' concerns are somatic distress, they often seek help in non-psychiatric clinics. However, the symptoms are usually medically unexplained. This group of diagnoses can be managed from the psychiatric perspective, including medications and psychotherapies. However, many patients do not receive psychiatric management in current medical practice. The goal of this project is to establish an association named "psychosomatic center" for providing comprehensive evaluations and treatments to the somatoform patients. Besides the psychiatrist, a case manager, a clinical psychologist, and a research assistant will be included in this association for the purposes of connection, performing psychotherapy and examinations. After entering the psychosomatic clinic, the investigators will routinely perform diagnostic interview, measure psychological and physiological features, and arrange individualized treatment program. The investigators will follow the important psychological and biological indexes every 3-6 months for building a cohort. At the same time, the case manager will connect with non-psychiatric clinics for ensuring the patients physical problems to be managed. The investigators expect this project to enhance the quality of treatment on the patients, to reduce the excessive examinations for the frequent attenders, and to improve the emotional burden of medical staffs.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1000 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Case management, a case manager will actively contact and follow the patient's physical and psychological conditions, and provide disease-specific psychoeducation; psychotherapy for patients with somatoform disorders (combined cognitive-behavioral treatment and biofeedback therapy)Case management, a case manager will actively contact and follow the patient's physical and psychological conditions, and provide disease-specific psychoeducation; psychotherapy for patients with somatoform disorders (combined cognitive-behavioral treatment and biofeedback therapy)
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Build a Psychosomatic Research Clinic for Providing Comprehensive Managements to Somatoform Patients
Anticipated Study Start Date :
Apr 1, 2021
Anticipated Primary Completion Date :
Mar 31, 2022
Anticipated Study Completion Date :
Mar 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Set a case management model for somatoform patients

Somatoform patients receiving case management, single group assignment, open label

Behavioral: CM
Case management, a case manager will actively contact and follow the patient's physical and psychological conditions, and provide disease-specific psychoeducation

Other: Time-limited psychotherapy for somatoform patients

Somatoform patients receiving psychotherapy (based on cognitive-behavioral therapy and biofeedback therapy) vs treatment as usual, open label, non-randomized

Behavioral: P/T
Psychotherapy, based on both cognitive-behavioral therapy and biofeedback therapy, structuralized, 6-10 sessions, performed by a psychiatrist or psychologist

Outcome Measures

Primary Outcome Measures

  1. Changes from baseline Patient Health Questionnaire-15 (PHQ-15) score at 3 months and 6 months (for psychotherapy); changes from baseline PHQ-15 score at 3, 6, 12, 24 months (for case management) [3, 6 months after initiating psychotherapy (for psychotherapy); 3, 6, 12, 24 months after initiating case management (for case management)]

    PHQ-15 is a scale rating the severity of somatic distress. It is a 3-point Likert scale with 15 items. The scores range from 0 (lowest level of somatic distress) to 30 (highest level of somatic distress).

  2. Changes from baseline Health Anxiety Questionnaire (HAQ) score at 3 months and 6 months (for psychotherapy); changes from baseline HAQ score at 3, 6, 12, 24 months (for case management) [3, 6 months after initiating psychotherapy (for psychotherapy); 3, 6, 12, 24 months after initiating case management (for case management)]

    HAQ is a scale rating the severity of health anxiety. It is a 4-point Likert scale with 21 items. The scores range from 0 (lowest level of health anxiety) to 63 (highest level of health anxiety).

Secondary Outcome Measures

  1. Scores of Scale for the Assessment of Illness Behavior (SAIB) [3, 6, 12, 24 months]

    SAIB is a scale rating the illness behavior. It is a 4-point Likert scale with 25 items. The scores range from 0 to 75.

  2. Scores of Cognition About Body and Health Questionnaire (CABAH) [3, 6, 12, 24 months]

    CABAH is a scale rating the cognition about health anxiety. It is a 4-point Likert scale with 39 items. The scores range from 0 to 117.

  3. Scores of Beck Depression Inventory-II (BDI- II) [3, 6, 12, 24 months]

    BDI- II is a scale rating the severity of depression. It is a 4-point Likert scale with 21 items. The scores range from 0 (lowest level of depression) to 63 (highest level of depression).

  4. Scores of Beck Anxiety Inventory (BAI) [3, 6, 12, 24 months]

    BAI- II is a scale rating the severity of anxiety. It is a 4-point Likert scale with 21 items. The scores range from 0 (lowest level of anxiety) to 63 (highest level of anxiety).

  5. Penn State Worry Questionnaire (PSWQ) [3, 6, 12, 24 months]

    PSWQ-16 is a scale rating the severity of worry. It is 5-point Likert scale with 16 items. The scores range from 1 (lowest level of worry) to 80 (highest level of worry).

  6. Scores of WHOQOL-BREF [3, 6, 12, 24 months]

    It is a self-report questionnaire measuring health-related quality of life. It is a 4-point Likert scale with 28 items, which belong to 5 domains (the overall, physical, psychological, social and environmental domains). The scores of each domain are usually normalized with 0-20 or 0-100.

  7. Changes from baseline standard deviation of normal to normal RR intervals (SDNN) [3, 6, 12, 24 months]

    SDNN reflects all the cyclic components responsible for variability in the period of recording, therefore it represents total variability.

  8. Changes from baseline high-frequency power (HF) [3, 6, 12, 24 months]

    HF component of HRV represents parasympathetic activity.

  9. Changes from baseline ratio of low-frequency power to high-frequency power (LF/HF) [3, 6, 12, 24 months]

    LF/HF was considered to reflect sympathovagal balance by some scholars.

  10. Changes from baseline value of skin conductance. [3, 6, 12, 24 months]

    In skin conductance, an electrodermograph imposes an imperceptible current across the skin and measures how easily it travels through the skin. Skin conductance is usually considered as a biomarker of sympathetic activity.

  11. Changes from baseline value of Respiratory sinus arrhythmia [3, 6, 12, 24 months]

    Respiratory sinus arrhythmia is an index combining the heart rate and respiratory signal, it represents parasympathetic activity.

  12. Changes from baseline value of Finger temperature. [3, 6, 12, 24 months]

    Finger temperature is found to be related to emotional disturbance (such as depression and anxiety), and it is often used in biofeedback therapy.

  13. Changes from baseline value of electromyogram [3, 6, 12, 24 months]

    Electromyogram is found to be related to emotional disturbance (such as depression and anxiety), and it is often used in biofeedback therapy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
    1. Between 15 and 80 years old
    1. Meet the diagnosis of DSM-5 somatic symptom disorder
Exclusion Criteria:
    1. With psychotic symptoms (such as schizophrenia, bipolar disorder with psychotic symptoms) or cognitive impairment
    1. Having potentially lethal physical diseases (such as cancer, coronary artery diseases, cerebrovascular diseases; because under this condition, high health anxiety is quite rational. Patients with common physical diseases can still enter this trial)
    1. Unable to read or understand the questionnaires

Contacts and Locations

Locations

Site City State Country Postal Code
1 National Taiwan University Hospital Yunlin Branch Douliu Taiwan

Sponsors and Collaborators

  • National Taiwan University Hospital
  • National Taiwan University Hospital, Yun-Lin Branch

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT04835103
Other Study ID Numbers:
  • 201812052RIND
First Posted:
Apr 8, 2021
Last Update Posted:
Apr 8, 2021
Last Verified:
Jan 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by National Taiwan University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 8, 2021